ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2997

A Genome-Wide Association Study of a Hispanic Systemic Sclerosis Cohort

Lara Bossini-Castillo1, Enrique Raya2, John D. Reveille3, Shervin Assassi4, Olga Y Gorlova5, Dinesh Khanna6, Daniel E. Furst7, Suzanne Kafaja8, Robert W. Simms9, Robert Lafyatis9, Tracy M. Frech10, Virginia D. Steen11, Barri J. Fessler12, Jerry A. Molitor13, Marta Alarcón-Riquelme14,15, Javier Martín16 and Maureen D Mayes4, 1Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS Granada, Granada, Spain, 2Rheumatology, Hospital Clínico San Cecilio, Granada, Spain, 3Internal Medicine/Rheumatology, University of Texas Medical School at Houston, Houston, TX, 4Rheumatology, University of Texas Medical School at Houston, Houston, TX, 5Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH, 6Division of Rheumatology, University of Michigan, Ann Arbor, MI, 7Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 8Rheumatology, University of California Los Angeles, Los Angeles, CA, 9Rheumatology, Boston University School of Medicine, Boston, MA, 10Div of Rheumatology, University of Utah, Salt Lake City, UT, 11Department of Rheumatology, Georgetown University Medical Center, Washington, DC, 12Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 13Rheumatology, University of Minnesota, Minneapolis, MN, 14Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma, OK, 15Centre for Genomics and Oncological Research (GENYO), Pfizer–University of Granada–Junta de Andalucia, Parque Tecnológico de la Salud (PTS), Granada, Spain, 16Instituto de Parasitología y Biomedicina López- Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: GWAS, Hispanic patients, polymorphism and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Genome-wide association studies (GWASs) have resulted in the identification of several genetic loci involved in systemic sclerosis (SSc) susceptibility. However, GWASs are normally focused in white European ancestry populations. Indeed, in the case of SSc this hypothesis-free approach has not been followed in mixed populations such as Hispanic Americans. It should be considered that the genetic polymorphisms described in whites do not cover all the variation observed in other ethnic groups. Moreover, due to the difference linkage-disequilibrium patterns, the analysis of cohorts of multiple ancestries contributes to fine-mapping and causal variant identification. Therefore, the aim of our study was to analyze for the first time the genetic background of SSc in a Hispanic American population.

Methods: Our study comprised a total of 285 SSc patients and 261 ethnically matched healthy controls. All SSc cases and 131 controls were recruited in Houston (Texas, USA) and genotyped using the HumanOmni2.5-8 Illumina Array. Statistical power was increased by adding 130 additional controls of Hispanic descent, recruited in Oklahoma City (Oklahoma, USA) and genotyped using the HumanOmni1-Quad Illumina BeadChip. After stringent per variant and per individual quality controls, 307,939 single-nucleotide polymorphisms (SNPs) were included in our analysis. Despite the mixed ancestry of the Hispanic population in the USA, the majority of the analyzed individuals in our study, both cases and controls, were of Mexican origin. Nevertheless, stringent principal component analysis filters were applied to verify case-control overlap. Significance was calculated using 2×2 contingency tables and Fisher’s exact test or χ 2 when necessary, to obtain p-values, odds ratios and 95% confidence intervals using PLINK (v1.07) software. Genomic correction was used to correct for multiple testing.

Results: We observed genome-wide level associations in the HLA region, specifically in the HLA class II region (between the HLA-DRB1 and the HLA-DQA1 loci). However, we did not report any signal outside the HLA region that reached the genome-wide significance threshold. Nevertheless, we found nominally associated SNPs in a number of SSc-related loci, identified in white populations. The regions showing nominal associations included: IRF5, STAT4, CD247, BLK, BANK1, IRF8, IRF7, IL12A, ATG5, PPARG. It should be noted that, despite the replication of firm SSc-risk factors in the Hispanic population, the most associated variants for each loci were not normally the same than in white populations.

Conclusion: Our findings support a common genetic background for SSc susceptibility between white European and Hispanic populations. Nonetheless, our results also revealed that the associated variants were not necessarily the same in both populations. These findings may be a basis for causal variant identification in the shared loci.


Disclosure: L. Bossini-Castillo, None; E. Raya, None; J. D. Reveille, None; S. Assassi, None; O. Y. Gorlova, None; D. Khanna, None; D. E. Furst, Gilead, 2,GlaxoSmithKline, 2,NIH, 2,Novartis Pharmaceutical Corporation, 2,Pfizer Inc, 2,Roche Pharmaceuticals, 2,Genentech and Biogen IDEC Inc., 2,UCB, 2,Abbvie, 5,Actelion Pharmaceuticals US, 5,Amgen, 5,Bristol-Myers Squibb, 5,Cytori, 5,Janssen Pharmaceutica Product, L.P., 5,Gilead, 5,GlaxoSmithKline, 5,NIH, 5,Novartis Pharmaceutical Corporation, 5,Pfizer Inc, 5,Roche Pharmaceuticals, 5,Genentech and Biogen IDEC Inc., 5,UCB, 5,Abbvie, 8,Actelion Pharmaceuticals US, 8,Bristol-Myers Squibb, 2,Amgen, 2,Actelion Pharmaceuticals US, 2,Abbvie, 2,UCB, 8; S. Kafaja, None; R. W. Simms, None; R. Lafyatis, None; T. M. Frech, None; V. D. Steen, None; B. J. Fessler, None; J. A. Molitor, None; M. Alarcón-Riquelme, None; J. Martín, None; M. D. Mayes, None.

To cite this abstract in AMA style:

Bossini-Castillo L, Raya E, Reveille JD, Assassi S, Gorlova OY, Khanna D, Furst DE, Kafaja S, Simms RW, Lafyatis R, Frech TM, Steen VD, Fessler BJ, Molitor JA, Alarcón-Riquelme M, Martín J, Mayes MD. A Genome-Wide Association Study of a Hispanic Systemic Sclerosis Cohort [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/a-genome-wide-association-study-of-a-hispanic-systemic-sclerosis-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-genome-wide-association-study-of-a-hispanic-systemic-sclerosis-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology